ATE399762T1 - Amidinderivate als selektive nmda- rezeptorantagonisten - Google Patents

Amidinderivate als selektive nmda- rezeptorantagonisten

Info

Publication number
ATE399762T1
ATE399762T1 AT01938439T AT01938439T ATE399762T1 AT E399762 T1 ATE399762 T1 AT E399762T1 AT 01938439 T AT01938439 T AT 01938439T AT 01938439 T AT01938439 T AT 01938439T AT E399762 T1 ATE399762 T1 AT E399762T1
Authority
AT
Austria
Prior art keywords
nmda receptor
derivatives
receptor antagonists
amidene
selective nmda
Prior art date
Application number
AT01938439T
Other languages
English (en)
Inventor
Neil Roy Curtis
Janusz Jozef Kulagowski
Steve Thomas
Alan Paul Watt
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE399762T1 publication Critical patent/ATE399762T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40Acylated substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/14Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Treatment Of Sludge (AREA)
  • Fertilizers (AREA)
  • Treating Waste Gases (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
AT01938439T 2000-06-23 2001-06-14 Amidinderivate als selektive nmda- rezeptorantagonisten ATE399762T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0015488.0A GB0015488D0 (en) 2000-06-23 2000-06-23 Therapeutic agents

Publications (1)

Publication Number Publication Date
ATE399762T1 true ATE399762T1 (de) 2008-07-15

Family

ID=9894319

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01938439T ATE399762T1 (de) 2000-06-23 2001-06-14 Amidinderivate als selektive nmda- rezeptorantagonisten

Country Status (8)

Country Link
EP (1) EP1296940B1 (de)
JP (1) JP2004501136A (de)
AT (1) ATE399762T1 (de)
AU (2) AU6411601A (de)
CA (1) CA2412164C (de)
DE (1) DE60134645D1 (de)
GB (1) GB0015488D0 (de)
WO (1) WO2001098262A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
CA2550679A1 (en) * 2003-12-23 2005-07-14 Schering Corporation Substituted n-aryl amidines as selective d1 dopamine receptor antagonists for the treatment of obesity and cns disorders
HUP0401523A3 (en) * 2004-07-29 2007-05-02 Richter Gedeon Vegyeszet Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them
KR20080035294A (ko) * 2006-10-19 2008-04-23 한국과학기술연구원 1,2-디[2-메톡시-4-(2-카르복실비닐)]페녹시에탄 화합물을유효성분으로 함유하는 파킨슨병 예방 및 치료용 약학적조성물
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
SI2091948T1 (sl) 2006-11-30 2012-07-31 Probiodrug Ag Novi inhibitorji glutaminil ciklaze
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
EP2142514B1 (de) 2007-04-18 2014-12-24 Probiodrug AG Thioharnstoffderivate als glutaminylcyclaseinhibitoren
ES2548913T3 (es) 2009-09-11 2015-10-21 Probiodrug Ag Derivados heterocíclicos como inhibidores de glutaminil ciclasa
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ(qc、ec2.3.2.5)の複素環阻害剤
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
JP6042968B2 (ja) 2012-04-20 2016-12-14 ユセベ ファルマ ソシエテ アノニム パーキンソン病の処置方法
CN106905273B (zh) * 2017-01-18 2019-05-14 中山大学 4-氧杂-4,5,6,7-四氢苯并[b]呋喃-3-羧酸类化合物及其应用
EP3461819B1 (de) 2017-09-29 2020-05-27 Probiodrug AG Hemmer der glutaminylcyclase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3476768A (en) * 1965-05-17 1969-11-04 Pfizer & Co C Thienylalanine
IL26870A (en) * 1965-12-30 1971-01-28 Pfizer Imidazoline and tetrahydropyrimidine derivatives,their preparation and use
JPH10287637A (ja) * 1997-04-14 1998-10-27 Banyu Pharmaceut Co Ltd アミジン誘導体

Also Published As

Publication number Publication date
AU2001264116B2 (en) 2006-04-13
AU6411601A (en) 2002-01-02
EP1296940A1 (de) 2003-04-02
WO2001098262A1 (en) 2001-12-27
GB0015488D0 (en) 2000-08-16
DE60134645D1 (de) 2008-08-14
JP2004501136A (ja) 2004-01-15
CA2412164C (en) 2010-10-26
EP1296940B1 (de) 2008-07-02
CA2412164A1 (en) 2001-12-27

Similar Documents

Publication Publication Date Title
ATE399762T1 (de) Amidinderivate als selektive nmda- rezeptorantagonisten
HK1049284A1 (en) Benzimidazole compounds having nociceptin receptoraffinity
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
ZA200007694B (en) EP4 receptor selective agonists in the treatment of osteoporosis.
HK1068783A1 (en) Methods for increasing the therapeutic response to electroconvulsive therapy ("ect")
AU1327501A (en) Device for delivering biological agents
WO2004009616A3 (en) Ghrelin analogs
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
NO994850L (no) Farmakologiske midler
ES2112546T3 (es) Benz(b)azepina-2,5-dionas utiles en el tratamiento de trastornos neurodegenerativos.
EP1007553A4 (de) Toxinrezeptoren aus zonula occludens
MY137620A (en) Therapeutic treatment
AU2002217668A1 (en) Activity aid apparatus
WO2002034240A3 (en) Delayed and sustained release formulations and method of use thereof
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
NO996044D0 (no) Rapamycinformuleringer for oral administrasjon
GB9811221D0 (en) Bacterial-pheromones and uses therefor
MY127675A (en) Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
IL156069A0 (en) Use of a substance which binds to sarp-1 receptor or influences the activity of endogenous sarp-1 in scleroderma
MXPA02006772A (es) Dispositivo para evitar o aliviar dolores en la espalda baja.
AU2001258442A1 (en) Drug delivery device, especially for the delivery of levonorgestrel
AU6846300A (en) Use of cyamemazine for cold turkey benzodiazepine treatment
MXPA03004195A (es) Terapia combinada para los trastornos dependientes de estrogenos.
TR200103126T2 (tr) Yapısal titremenin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri
FR2800615B1 (fr) Produit comprenant au moins une substance inhibitrice des no synthases en association avec au moins une substance inhibitrice des phospholipases a2

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties